Drug Profile
Clemizole - Eiger BioPharmaceuticals Inc
Alternative Names: Clemizole hydrochlorideLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eiger BioPharmaceuticals
- Developer Eiger BioPharmaceuticals; Eiger BioPharmaceuticals, Inc.
- Class Antiallergics; Antiepileptic drugs; Antihistamines; Benzimidazoles; Small molecules
- Mechanism of Action Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C; Liver cancer
Most Recent Events
- 17 Sep 2020 Discontinued - Phase-II for Liver cancer in Turkey (PO) (Eiger BioPharmaceuticals pipeline, September 2020)
- 06 Mar 2017 Discontinued - Phase-I for Hepatitis C in Australia and New Zealand (PO)
- 13 Feb 2017 Phase-II clinical trials in liver cancer in Turkey (PO) (NCT03069508)